One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

Journal of Clinical Oncology

Volumn 26, Issue 18, 2008, Pages 3063-3072

  Yao, James C ^a   Hassan, Manal ^a   Phan, Alexandria ^a   Dagohoy, Cecile ^a   Leary, Colleen ^a   Mares, Jeannette E ^a   Abdalla, Eddie K ^a   Fleming, Jason B ^a   Vauthey, Jean Nicolas ^a   Rashid, Asif ^a   Evans, Douglas B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOID; ADULT; AFRICAN AMERICAN; AGED; AMERICAN INDIAN; ARTICLE; ASIAN; ATYPICAL CARCINOID; CANCER INCIDENCE; CANCER REGISTRY; CANCER SURVIVAL; CARCINOID; COMPOSITE CARCINOID; CONTROLLED STUDY; DISEASE COURSE; ENTEROCHROMAFFIN CELL CARCINOID; ENTEROCHROMAFFIN LIKE CELL TUMOR; ENTEROGLUCAGONOMA; EXOCRINE ADENOCARCINOMA; FEMALE; GASTRINOMA; GLUCAGONOMA; GOBLET CELL CARCINOID; HISTOLOGY; HISTORY; HUMAN; HUMAN TISSUE; INSULINOMA; LUNG; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUROENDOCRINE CARCINOMA; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; PACIFIC ISLANDER; PANCREAS ISLET CELL CARCINOMA; PARAGANGLIOMA; PHEOMOCHROMOCYTOMA; PHYSICIAN; POPULATION; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RACE; RECTUM; SOMATOSTATINOMA; STATISTICAL SIGNIFICANCE; UNITED STATES; VIPOMA; INCIDENCE; MIDDLE AGED; REVIEW;

CARCINOID TUMOR; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROGNOSIS; SEER PROGRAM; UNITED STATES;

EID: 46449110634     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.4377     Document Type: Article

References (17)

1. Obendorfer S: Karzinoide tumoren des dunndarms. Frankf Z Pathol 1:425-429, 1907
2. Godwin JD: Carcinoid tumors. An analysis of 2,837 cases. Cancer 36:560-569, 1975
3. Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97:934-959, 2003
4. Lepage C, Rachet B, Coleman MP: Survival from malignant digestive endocrine tumors in England and wales: A population-based study. Gastroenterology 132:899-904, 2007
5. Yao JC, Eisner MP, Leary C, et al: Populationbased study of islet cell carcinoma. Ann Surg Oncol 14:3492-3500, 2007
6. Fritz AG: International Classification of Diseases for Oncology: ICD-O (ed 3). Geneva, Switzerland, World Health Organization, 2000
7. Surveillance, Epidemiology, and End Results (SEER) Program: SEER*Stat Database: SEER 17 Regs Nov 2006 sub (1973-2004). Bethesda, MD, National Cancer Institute, 2007
8. Gail MH, Kessler L, Midthune D, et al: Two approaches for estimating disease prevalence from population-based registries of incidence and total mortality. Biometrics 55:1137-1144, 1999
9. Gigli A, Mariotto A, Clegg LX, et al: Estimating the variance of cancer prevalence from population-based registries. Stat Methods Med Res 15:235-253, 2006
10. Byrne J, Kessler LG, Devesa SS: The prevalence of cancer among adults in the United States: 1987. Cancer 69:2154-2159, 1992
11. SEER Cancer Statistics Review, 1975-2004. http://seer.cancer.gov/csr/ 1975_2004/
12. Schally A: Oncological applications of somatostatin analogue. Cancer Res 48:6977-6985, 1988
13. Hillman N, Herranz L, Alvarez C, et al: Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan). Exp Clin Endocrinol Diabetes 106:226-230, 1998
14. Oberg K: Treatment of neuroendocrine tumors. Cancer Treat Rev 20:331-355, 1994
15. Kulke MH, Mayer RJ: Carcinoid tumors. N Engl J Med 340:858-868, 1999
16. Schnirer II, Yao JC, Ajani JA: Carcinoid: A comprehensive review. Acta Oncol 42:672-692, 2003
17. Yao JC: Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab 21:163-172, 2007